57 Matching Annotations
  1. Last 7 days
    1. In January 2013, a 74-year-old man was admitted to the Department of Neurosurgery at Yonsei University College of Medicine due to gait disturbance and tingling sensation of both legs. The patient was receiving beta-adrenergic antagonist and calcium channel blocker for arterial hypertension. He had lost his vision in the left eye due to cataract and amblyopia in the right eye due to retinitis which had occurred 30 years ago. The patient’s family history included a mother with a brain tumor of unconfirmed pathology, and both brothers with renal cell carcinoma with VHL gene mutation (Fig. 1). Serum carcinoembryonic antigen (CEA) was elevated to 11.78 ng/mL (normal value, 0.0 to 5.0 ng/mL). Although he had no history of diabetes mellitus, serum glucose level was 462 mg/dL and HbA1c was 11.7%, which led to a new diagnosis of diabetes mellitus, and initiation of insulin therapy. Whole spine magnetic resonance imaging (MRI) showed multiple enhancing nodular lesions of the spinal canal suspected leptomeningeal metastasis of unknown primary malignancy (Fig. 2A). Positron emission tomography whole body scan showed intense fludeoxyglucose uptake in a 3-cm-sized heterogeneous mass in the right kidney and focal mural thickening in the sigmoid colon (Fig. 2B and ​andC).C). Colonoscopy showed a 5-cm-sized ulceroinfiltrative lesion in the sigmoid colon and a polypoid lesion in the rectum. Subsequent histological examination confirmed the diagnosis of adenocarcinoma and high grade tubular adenoma with focal carcinoma in situ transformation, respectively. Incisional biopsy of the spinal mass was performed and the histological examination revealed hemangioblastoma.Open in a separate windowFig. 1.Pedigree presenting VHL gene mutation status and malignancy. Both brothers were diagnosed with renal cell carcinoma (RCC) with VHL gene mutation and one of his sons was confirmed VHL mutation without clinical manifestation.Open in a separate windowFig. 2.(A) Spine magnetic resonance imaging showed multiple enhancing nodular lesions of the spinal canal suspected leptomeningeal metastasis of unknown primary malignancy. Positron emission tomography computed tomography whole body scan showed a 3-cm enhancing heterogenous mass in the right kidney (arrow) (B), focal mural thickening with intense fludeoxyglucose uptake in the sigmoid colon (C).The patient underwent laparoscopic right partial nephrectomy, laparoscopic anterior resection of the sigmoid colon, and transanal endoscopic operation of the rectum. Histologic examination of the kidney revealed renal clear cell carcinoma (size, 1.9×1.7 cm), Fuhrman nuclear grade 3 (pT1aN0M0; stage I). In the sigmoid colon, gross pathology showed an ulcerofungating tumor (size, 4.2×3.6 cm) and 3 of 23 examined regional lymph nodes were metastasis. Subsequent histological examination confirmed typical features of colon adenocarcinoma (pT3N1bM0; stage IIIB). The rectum specimen was confirmed to be a 0.5-cm-sized well differentiated adenocarcinoma (pT1N0M0; stage I). The postoperative CEA level was 4.24 ng/mL.Regarding clinical decision processes, we initially suspected VHL disease. Subsequently, polymerase chain reaction (PCR) sequencing analysis of VHL gene showed p.Glu70Lys (c.208G > A) mutation in exon 1, confirming the diagnosis of VHL disease (Fig. 3). Result of endocrine hormonal evaluation for pheochromocytoma was within normal range.Open in a separate windowFig. 3.Polymerase chain reaction sequencing analysis of von Hippel–Lindau (VHL) gene showed a p.Glu70Lys (c.208G > A) mutation in exon 1, confirming the diagnosis of VHL disease.His two sons were screened for VHL disease using PCR sequencing analysis, and one progenity showed p.Glu70Lys (c.208G > A) mutation in exon 1, identical to his father. He underwent ophthalmic examination, abdomen-pelvic computed tomography scan and blood test for catecholamine metabolites, but there were no abnormal findings.After 3 weeks from discharge, he was admitted to hospital complaining of worsened gait disturbance and numbness of both soles. Brain MRI showed three enhancing lesions in bilateral cerebellar hemispheres and left cerebellar tonsil, suggesting hemangioblastomas (Fig. 4). The patient underwent gamma knife surgery in cerebellar lesions and palliative radiotherapy to T9-S1 spine with a total of 45 Gy in 25 daily fractions.Open in a separate windowFig. 4.Brain magnetic resonance imaging showed three enhancing lesions (arrows) in bilateral cerebellar hemispheres (A,B) and left cerebellar tonsil (C), suggesting hemangioblastomas.nAfter one month, follow-up imaging studies showed stable lesions in the brain and spine, but there was a newly developed hepatic metastasis in S6 and an enlarged aortocaval lymph node (Fig. 5). Concurrent serum CEA level increased to 19.54 ng/mL. The multidisciplinary team decided to perform surgery, laparoscopic wedge resection of liver and excision of aortocaval lymph node. Histologic examination of liver revealed a 1.6×1.2-cm-sized metastatic adenocarcinoma, moderately differentiated, clinically from colon. Pathologic finding indicated that the aortocaval lymph node was metastatic carcinoma, favoring renal clear cell carcinoma. He is on regular follow-up in the outpatient clinic and imaging studies show no evidence of recurrence and CEA level is stabilized within normal range.

      PatientID: None (Proband)

      KindredID: 1

      Case: M, 74Y0M, Ethnicity Unknown

      DiseaseAssertion: VHL

      FamilyInfo:Mother with a brain tumor of unconfirmed pathology, and both brothers (70Y and 79Y) with renal cell carcinoma with the same VHL gene mutation as this patient. One son (44Y) has the same mutation but was asymptomatic. Daughter (40Y) had a brain hemorrhage, niece had hematologic malignancy, nephew has pancreatic cancer; genetic information is unclear or not provided for these family members.

      CasePresentingHPOs: HP:0010797; HP:0000822; HP:0000518; HP:0000572; HP:0000646; HP:0000819; HP:0040276; HP:0006770; HP:0032118, HP:0030439; HP:0009713; HP:0002672; HP:0006880 (Hemangioblastoma, Hypertension, Cataract, Visual loss, Amblyopia, Diabetes mellitus, Adenocarcinoma of the colon, Clear cell renal cell carcinoma, Retinitis, Anal canal adenocarcinoma, Spinal hemangioblastoma, Gastrointestinal carcinoma, Cerebellar hemangioblastoma)

      CaseHPOFreeText: History of arterial hypertension and retinitis causing loss of vision in the left eye due to cataract and amblyopia in the right eye. History of retinal hemangioblastoma was presumed. Diagnosed with diabetes mellitus at the time of the study. MRI showed multiple enhancing nodular lesions of the spinal canal, later confirmed to be a hemangioblastoma. Whole body PET scan showed a heterogeneous mass in the right kidney and focal mural thickening in the sigmoid colon. Colonoscopy showed an ulceroinfiltrative lesion in the sigmoid colon and a polypoid lesion in the rectum subsequently confirmed as a adenocarcinoma and high grade tubular adenoma with focal carcinoma, respectively. Histologic examination of the kidney revealed renal clear cell carcinoma. In the sigmoid colon, gross pathology showed an ulcerofungating tumor and some regional lymph nodes were metastasis. The rectum specimen was confirmed to be a well differentiated adenocarcinoma. Brain MRI showed three enhancing lesions in bilateral cerebellar hemispheres and left cerebellar tonsil, suggesting hemangioblastomas. Histologic examination of liver revealed a metastatic adenocarcinoma. Pathologic finding indicated that the aortocaval lymph node was metastatic carcinoma, favoring renal clear cell carcinoma.

      CaseNotHPOs: N/A

      CaseNotHPOFreeText: N/A

      CasePreviousTesting: N/A

      PreviouslyPublished: N/A

      SupplementalData: Figure 1

      Variant: p.E70K (c.208G>A)

      LegacyVariant: N/A

      CaseProblemVariantFreeText: N/A

      ClinVarID: 43598, https://www.ncbi.nlm.nih.gov/clinvar/variation/43598/

      CAID: N/A

      gnomAD: 0.000004365, https://gnomad.broadinstitute.org/variant/3-10183739-G-A

      VariantEvidence: N/A

      MutationType: missense_variant;transition

      CivicName: E70K (c.208G>A)

      MultipleGeneVariants: N/A

    1. PatientID: 179

      KindredID: 70

      Case: F, 44Y0M, Chinese

      DiseaseAssertion: VHL

      FamilyInfo: The proband (patient 179) had a daughter (patient 180) who was confirmed with the mutation, and present4ed with a retinal angioma and multiple pancreatic cysts/tumors at 17. The proband also has three family members who were unconfirmed with the mutation (passed away before diagnosis): patient 181 (proband's brother) had a CNS hemangioblastoma at 17, patient 182 (proband's father) had a CNS hemangioblastoma at 49, renal cell carcinoma and multiple pancreatic cysts/tumors at 56, and patient 183 (proband's uncle) had a CNS hemangioblastoma at 32 and a retinal angioma at 30.

      CasePresentingHPOs: HP:0001737; HP:0001732; HP:0005584 (Pancreatic cysts, Abnormality of the pancreas, Renal cell carcinoma)

      CaseHPOFreeText: The proband presented with a renal cell carcinoma at 44, and multiple pancreatic cysts/tumors at 28.

      CaseNotHPOs: HP:0010797; HP:0002666; HP:0009711 (Hemangioblastoma, Pheochromocytoma, Retinal capillary hemangioma)

      CaseNotHPOFreeText: N/A

      CasePreviousTesting: N/A

      PreviouslyPublished: This patient was also published in a later paper by Wang et al., 2018 (PMID: 29330336).

      SupplementalData: Patient and family genotype-phenotype information is listed in Supplementary Table 1.

      Variant: p.C162* (c.486C>A)

      LegacyVariant: N/A

      CaseProblemVariantFreeText: N/A

      ClinVarID: 223226; https://www.ncbi.nlm.nih.gov/clinvar/variation/223226/

      CAID: N/A

      gnomAD: N/A

      VariantEvidence: N/A

      MutationType: missense_variant;transversion

      CivicName: C162* (c.486C>A)

      MultipleGeneVariants: N/A

    2. PatientID: 248

      KindredID: 95

      Case: F, 44Y0M, Chinese

      DiseaseAssertion: VHL

      FamilyInfo: The proband (patient 246) has an asymptomatic daughter (patient 247), a sister (patient 248) with renal cell carcinoma at age 44, and an asymptomatic nephew (patient 249) (son of sister), all confirmed with the mutation.

      CasePresentingHPOs: HP:0005584 (Renal cell carcinoma)

      CaseHPOFreeText: The proband's sister presented with renal cell carcinoma at age 44.

      CaseNotHPOs: HP:0009711; HP:0002666; HP:0010797; HP:0001737; HP:0001732 (Retinal capillary hemangioma, Pheochromocytoma, Hemangioblastoma, Pancreatic cysts, Abnormality of the pancreas)

      CaseNotHPOFreeText: N/A

      CasePreviousTesting: N/A

      PreviouslyPublished: This cohort was also published in an earlier paper by Wang et al., 2014 (PMID 24581539) as well as a later paper by Wang et al., 2018 (PMID: 29330336).

      SupplementalData: Patient and family genotype-phenotype information is listed in Supplementary Table 1.

      Variant: Exon 1 Deletion (c.1-?_340+?del)

      LegacyVariant: N/A

      CaseProblemVariantFreeText: N/A

      ClinVarID: N/A

      CAID: N/A

      gnomAD: N/A

      VariantEvidence: N/A

      MutationType: exon_loss_variant

      CivicName: Exon 1 Deletion

      MultipleGeneVariants: N/A

    3. PatientID: 251

      KindredID: 96

      Case: F, 44Y0M, Chinese

      DiseaseAssertion: VHL

      FamilyInfo: The proband (patient 250) presented with a CNS hemangioblastoma at 23, retinal angioma at 17, and multiple pancreatic cysts/tumors at 19. His mother (patient 251) presented with a CNS hemangioblastoma at age 43, retinal angioma at 35, renal cell carcinoma/multiple pancreatic cysts/tumors at 44.

      CasePresentingHPOs: HP:0010797; HP:0009711; HP:0001737; HP:0001732; HP:0005584 (Hemangioblastoma, Retinal capillary hemangioma, Pancreatic cysts, Abnormality of the pancreas, Renal cell carcinoma)

      CaseHPOFreeText: The patient's mother presented with a CNS hemangioblastoma at age 43, retinal angioma at 35, renal cell carcinoma/multiple pancreatic cysts/tumors at 44.

      CaseNotHPOs: HP:0002666 (Pheochromocytoma)

      CaseNotHPOFreeText: N/A

      CasePreviousTesting: N/A

      PreviouslyPublished: This cohort was also published in a later paper by Wang et al., 2018 (PMID: 29330336).

      SupplementalData: Patient and family genotype-phenotype information is listed in Supplementary Table 1.

      Variant: Exon 1 Deletion (c.1-?_340+?del)

      LegacyVariant: N/A

      CaseProblemVariantFreeText: N/A

      ClinVarID: N/A

      CAID: N/A

      gnomAD: N/A

      VariantEvidence: N/A

      MutationType: exon_loss_variant

      CivicName: Exon 1 Deletion

      MultipleGeneVariants: N/A

    1. PatientID: None

      KindredID: VHL3

      Case: F, 44Y0M, Ethnicity Unknown

      DiseaseAssertion: VHL

      FamilyInfo: N/A

      CohortInfo: A total of 190 patients recruited by the COMETE network over 15 years were included in the study.

      CasePresentingHPOs: HP:0002666 (Pheochromocytoma)

      CaseHPOFreeText: The patient had one benign pheochromocytoma.

      CaseNotHPOs: N/A

      CaseNotHPOFreeText: N/A

      CasePreviousTesting: RET/SDHB/SDHC/SDHD

      PreviouslyPublished: N/A

      SupplementalData: Table 1 of Supplementary

      Variant: p.R82G (c.244C>G)

      LegacyVariant: N/A

      CaseProblemVariantFreeText: N/A

      ClinVarID: 1297059, https://www.ncbi.nlm.nih.gov/clinvar/variation/1297059/

      CAID: N/A

      gnomAD: N/A

      VariantEvidence: The patient had LOH found in the BAC array CGH data.

      MutationType: missense_variant;transversion

      CivicName: R82G (c.244C>G)

      MultipleGeneVariants: N/A

    1. 6418Y18Y44NNNYNc.500G>AExon 3p.Arg167GlnMissense

      PatientID: 6

      KindredID: 4

      Case: Sex Unknown, 44Y0M, Ethnicity Unknown

      DiseaseAssertion: VHL

      FamilyInfo: Four other family members were found to have the same mutation (Patient 7,8,9,10).

      CasePresentingHPOs: HP:0002668, HP:0002666, HP:0030405, HP:0010797 (Paraganglioma, pheochromocytoma, pancreatic endocrine tumor, hemangioblastoma)

      CaseHPOFreeText: The patient was diagnosed with pancreatic endocrine tumor at age 44 and diagnosed with pheochromocytoma and paraganglioma at age 18.

      CaseNotHPOs: HP:0009711, HP:0001737, HP:0000107, HP:0005584 (retinal capillary hemangioma, pancreatic cysts, renal cyst, renal cell carcinoma)

      CaseNotHPOFreeText: N/A

      CasePreviousTesting: N/A

      PreviouslyPublished: N/A

      SupplementalData: N/A

      Variant: p.R167Q (c.500G>A)

      LegacyVariant: N/A

      CaseProblemVariantFreeText: N/A

      ClinVar: 2216 https://www.ncbi.nlm.nih.gov/clinvar/variation/2216/

      CAID: N/A

      gnomAD: 0.000003977 https://gnomad.broadinstitute.org/variant/3-10191507-G-A

      VariantEvidence:N/A

      MutationType: missense_variant;transition

      CivicName: R167Q (c.500 G >A)

      MultipleGeneVariants: N/A

  2. Nov 2026
    1. Family 6+2c.349T > G, p.Trp117GlyYes136444440–44

      PatientID: None

      KindredID: 6

      Case: Sex Unknown, 44Y0M, Chinese

      DiseaseAssertion: VHL

      FamilyInfo: Positive. Patient's son who was confirmed to have this mutation presented with hemangioblastoma at age 12. The patient's mother, aunt, grandmother, brother 1 and 2, and sister 3 all passed before they could undergo genetic testing but had a variety of VHL presentations. The patient's first sister and third nephew were confirmed to have this genetic mutation. The first sister presented with abnormality of the pancreas at age 53. The nephew had hemangioblastoma and retinal angioma at age 13. Additional familial phenotypes can be found in Table 1.

      CasePresentingHPOs: HP:0010797, HP:0005584, HP:0001732, HP:0009711 (hemangioblastoma, renal cell carcinoma, abnormality of the pancreas, retinal capillary hemangioma)

      CaseHPOFreeText: The patient presented with hemangioblastoma at age 36. At age 40 he/she presented with pancreatic cysts or tumours. At age 44 the patient had retinal angioma, renal cell carcinoma, and epididymal or ovarian cystadenoma.

      CaseNotHPOs: HP:0002666 (pheochromocytoma)

      CaseNotHPOFreeText: N/A

      CasePreviousTesting: N/A

      PreviouslyPublished: 29330336

      Variant: p.W117G (c.349T>G)

      LegacyVariant:N/A

      CaseProblemVariantFreeText: N/A

      ClinVarID: 862346 https://www.ncbi.nlm.nih.gov/clinvar/variation/862346/

      CAID: N/A

      gnomAD: N/A

      VariantEvidence: N/A

      MutationType: missense_variant;transversion

      CivicName:W117G (c.349T>G)

      MultipleGeneVariants: N/A

    1. 13MProbandExon2, 3 deletion1324444, B–41–4

      PatientID: Proband

      KindredID: 13

      Case: M, 44Y0M, Korean

      DiseaseAssertion: VHL

      FamilyInfo: Son and brother presented with the same VHL variant. Son is asymptomatic. Brother presented with CNS hemangioblastoma at 29Y, retinal hemangioblastoma at 52Y, bilateral RCC at 43Y, multiple pancreatic lesions (pancreatic cyst or tumor, unspecified) at 43Y and bilateral renal cysts at 43Y. Nephew presented with CNS hemangioblastoma at 22Y, retinal hemangioblastoma at 18Y, bilateral RCC at 29Y and multiple pancreatic lesions (pancreatic cyst or tumor, unspecified) at 18Y but was not genetically confirmed.

      CohortInfo: Thirteen unrelated patients with germline VHL mutations who were diagnosed with VHL disease were evaluated.

      CasePresentingHPOs: HP:0001732; HP:0010797; HP:0005584; HP:0009711 (Abnormality of the pancreas, Hemangioblastoma, Renal cell carcinoma, Retinal capillary hemangioma)

      CaseHPOFreeText: CNS hemangioblastoma at 32Y, retinal hemangioblastoma at 44Y, bilateral RCC at 44Y and multiple pancreatic lesions (pancreatic cyst or tumor, unspecified) at 41Y. Diagnosed with VHL Type 1.

      CaseNotHPOs: HP:0000107; HP:0002666 (Renal cyst, Pheochromocytoma)

      CaseNotHPOFreeText: N/A

      CasePreviousTesting: N/A

      PreviouslyPublished: N/A

      SupplementalData: N/A

      Variant: Exon 2-3 Deletion (c.341-?_642+?del)

      LegacyVariant: N/A

      CaseProblemVariantFreeText: N/A

      ClinVarID: N/A

      CAID: N/A

      gnomAD: N/A

      VariantEvidence: N/A

      MutationType: exon_loss_variant

      CivicName: Exon 2-3 Deletion

      MultipleGeneVariants: N/A

    1. PatientID: 160

      KindredID: 61

      Case: M, 44Y0M, Chinese

      DiseaseAssertion: VHL

      FamilyInfo: N/A

      CasePresentingHPOs: HP:0005584 (Renal cell carcinoma)

      CaseHPOFreeText: The proband presented with a renal cell carcinoma at age 44.

      CaseNotHPOs: HP:0009711; HP:0002666; HP:0010797; HP:0001737; HP:0001732 (Retinal capillary hemangioma, Pheochromocytoma, CNS Hemangioblastoma, Pancreatic cysts, Abnormality of the pancreas)

      CaseNotHPOFreeText: N/A

      CasePreviousTesting: N/A

      PreviouslyPublished: This cohort was also published in a later paper by Wang et al., 2018 (PMID: 29330336).

      SupplementalData: Patient and family genotype-phenotype information is listed in Supplementary Table 1.

      Variant: p.R161* (c.481C>T)

      LegacyVariant: N/A

      CaseProblemVariantFreeText: N/A

      ClinVarID: 2217, https://www.ncbi.nlm.nih.gov/clinvar/variation/2217/

      CAID: N/A

      gnomAD: N/A

      VariantEvidence: N/A

      MutationType: missense_variant;transition

      CivicName: R161* (c.481C>T)

      MultipleGeneVariants: N/A

    2. PatientID: 41

      KindredID: 14

      Case: F, 44Y0M, Chinese

      DiseaseAssertion: VHL

      FamilyInfo: N/A

      CasePresentingHPOs: HP:0001737; HP:0001732; HP:0005584 (Pancreatic cysts, Abnormality of the pancreas, Renal cell carcinoma)

      CaseHPOFreeText: The proband presented with renal cell carcinoma and multiple pancreatic cysts/ tumors at age 44.

      CaseNotHPOs: HP:0010797; HP:0009711; HP:0002666 (Hemangioblastoma, Retinal capillary hemangioma, Pheochromocytoma)

      CaseNotHPOFreeText: N/A

      CasePreviousTesting: N/A

      PreviouslyPublished: This patient was also published in a later paper by Wang et al., 2018 (PMID: 29330336).

      SupplementalData: Patient and family genotype-phenotype information is listed in Supplementary Table 1.

      Variant: p.S80Ifs*79 (c.239del)

      LegacyVariant: N/A

      CaseProblemVariantFreeText: N/A

      ClinVarID: N/A

      CAID: CA913189245; https://reg.clinicalgenome.org/redmine/projects/registry/genboree_registry/allele?hgvsOrDescriptor=NM_000551.3%3Ac.239del

      gnomAD: N/A

      VariantEvidence: N/A

      MutationType: minus_1_frameshift_variant

      CivicName: S80fs (c.239del)

      MultipleGeneVariants: N/A

    1. PatientID: II-26

      KindredID: 1

      Case: M, 45Y0M, Ethnicity Unknown

      DiseaseAssertion: VHL

      FamilyInfo: Large multigenerational family with a history of both VHL and spinocerebellar ataxia type 2 (SCA2). Screening for clinical and genetic diagnostics were gathered as well as thorough information on non-living members. His two daughters also appeared to have the VHL mutation. See family pedigree (Fig. 1).

      CasePresentingHPOs: HP:0006880; HP:0009711; HP:0006770; HP:0009713; HP:0002031; HP:0003396; HP:0001649; HP:0001737; HP:0030424 (cerebellar hemangioblastoma, retinal capillary hemangioma, clear cell renal cell carcinoma, spinal hemangioblastoma, Abnormal esophagus morphology, Syringomyelia, Tachycardia, pancreatic cysts, epididymal cyst)

      CaseHPOFreeText: CNS (including retinal angiomas) and renal involvement; with cerebellum hemangioblastoma found at age 34Y. An oesophageal abnormality that was treated with vagotomy at age 35Y. At age 44Y had bilateral clear cell renal cancer resulting in a right partial nephrectomy and left total nephrectomy. Same year had spinal surgery to treat a syrinx associated with a spinal cord haemangioblastoma, as well as cystic lesions in the pancreas (consistent with epididymal cystadenoma).

      CaseNotHPOs: N/A

      CaseNotHPOFreeText: N/A

      CasePreviousTesting: N/A

      PreviouslyPublished: N/A

      SupplementalData: N/A

      Variant: p.E160Sfs*10 (c.477delA)

      LegacyVariant: c.688delA

      CaseProblemVariantFreeText: c.477del, p.Glu160Serfs10 should be used. Details: 477del same as 475delA bc that codon is AAA so doesn't matter which A gets deleted: there is an A at 475 476 477 so for HGVS we say that 477 (the latter) is deleted since that follows HGVS nomenclature. Thus use c.477del: p.Glu160Serfs10

      ClinVarID: 182959 https://www.ncbi.nlm.nih.gov/clinvar/variation/182959/

      CAID: N/A

      gnomAD: N/A

      VariantEvidence: N/A

      MutationType: minus_1_frameshift_variant

      CivicName: E160fs (c.477del)

      MultipleGeneVariants: N/A

  3. Oct 2026
    1. probands

      PatientID: 4

      KindredID: 4

      Case: Sex Unknown, 45Y0M, Chinese

      DiseaseAssertion: VHL

      FamilyInfo: Patient had no family history of VHL disease.

      CohortInfo: 16 Chinese patients clinically diagnosed with VHL disease.

      CasePresentingHPOs: HP:0010797; HP:0005584; HP:0001732 (hemangioblastoma; renal cell carcinoma; abnormality of the pancreas

      CaseHPOFreeText: The patient presented with a hemangioblastoma at age 34, as well as renal cell carcinoma and abnormality of the pancreas at age 44.

      CaseNotHPOs: HP:0009711, HP:0002666, HP:0030393 (retinal capillary hemangioma, pheochromocytoma, endolymphatic sac tumor)

      CaseNotHPOFreeText: N/A

      CasePreviousTesting: N/A

      PreviouslyPublished: N/A

      SupplementalData: N/A

      Variant: p.H115R (c.344A>G)

      LegacyVariant: N/A

      CaseProblemVariantFreeText: N/A

      ClinVarID: N/A

      CAID: CA70049376, https://reg.clinicalgenome.org/redmine/projects/registry/genboree_registry/allele?hgvsOrDescriptor=NM_000551.3%3Ac.344A%3EG

      gnomAD: N/A

      VariantEvidence: N/A

      MutationType: missense_variant; transition

      CivicName: H115R (c.344A>G)

      MultipleGeneVariants: N/A

    1. 5 patients with VHL disease (Figs. 1 and 2, and Table 1)

      PatientID: 4

      KindredID: 3

      Case: M, 45Y0M, Arab

      DiseaseAssertion: VHL

      FamilyInfo: No family history of VHL disease was described for this patient. Immediate family members were recommended to genetically test for the relevant variant or monitor for VHL-related symptoms.

      CasePresentingHPOs: HP:0006880; HP:0009713; HP:0000107; HP:0001737; HP:0000787 (cerebellar hemangioblastoma; spinal hemangioblastoma; renal cyst; pancreatic cysts; nephrolithiasis)

      CaseHPOFreeText: At 40Y, Patient 4 was diagnosed with spinal and cerebellar hemangioblastomas, as well as multiple renal and pancreatic cysts. He was diagnosed with VHL disease type 1. At 43Y, renal cysts and stones were discovered. A year later, more spinal hemangioblastomas and renal stones were found. A year later, cerebellar lesions, as well as renal and pancreatic cysts were reported (see table 1).

      CaseNotHPOs: HP:0002088; HP:0001392; HP:0005264; HP:0001743 (abnormal lung morphology; abnormality of the liver; abnormality of the gallbladder; abnormality of the spleen)

      CaseNotHPOFreeText: No lesions were observed in the lungs, liver, gallbladder, and spleen.

      CasePreviousTesting: N/A

      PreviouslyPublished: N/A

      SupplementalData:  N/A

      Variant: p.N90del (c.268_270del)

      LegacyVariant: N/A

      CaseProblemVariantFreeText: N/A

      ClinVarID: N/A

      CAID: CA645524783, https://reg.genome.network/redmine/projects/registry/genboree_registry/by_caid?caid=CA645524783

      gnomAD: N/A

      VariantEvidence: N/A

      MutationType: inframe_deletion

      CivicName: N90del (c.268_270del)

      MultipleGeneVariants: N/A

    2. Patient 1

      PatientID: 1

      KindredID: 1

      Case: M, 51Y0M, Arab

      DiseaseAssertion: VHL

      FamilyInfo: Patient 2 (the patient’s brother) presented with the same mutation and was diagnosed with VHL at age 45. The two brothers had very similar VHL clinical manifestations including cerebellar hemangioblastomas, renal cell carcinoma, and cysts in the pancreas. However, patient 1 had testicular and epididymal cysts, as well as lesions in the spine, which were absent in Patient 2. No other family history was noted. Immediate family members were recommended to genetically test for the relevant variant or monitor for VHL-related symptoms.

      CasePresentingHPOs: HP:0005584; HP:0009713; HP:0006880; HP:0000107; HP:0001737; HP:0030424; HP:0033608; HP:0000541; HP:0012215 (renal cell carcinoma; spinal hemangioblastoma; cerebellar hemangioblastoma; renal cyst; pancreatic cysts; epididymal cyst; pulmonary nodule; retinal detachment; testicular microlithiasis)

      CaseHPOFreeText: At 44Y, Patient 1 exhibited cerebellar and spinal hemangioblastomas, as well as retinal detachment. He also had renal cell carcinoma in both kidneys and multiple cysts in one kidney, testis, and pancreas. He also reported a history of headaches and vertigo, leading to a diagnosis of VHL disease type 1. At 49Y, multiple nodules were found in his lungs and a year later, a nodule in the testis and scrotal lithiasis were detected. At 51Y, renal cell carcinoma was identified in the left kidney and his left epididymis was enlarged. Patient continued to present with left testicular and scrotal lithiasis, right retinal detachment, and multiple nodules in both lungs. However, tMutation:Germlinehe lung phenotype was asymptomatic (see table 1).

      CaseNotHPOs: HP:0001392; HP:0005264; HP:0001743 (abnormality of the liver; abnormality of the gallbladder; abnormality of the spleen)

      CaseNotHPOFreeText: No lesions were observed in the liver, gallbladder, and spleen.

      CasePreviousTesting: N/A

      PreviouslyPublished: N/A

      SupplementalData:  N/A

      Variant: p.F76del (c.227_229del)

      LegacyVariant: N/A

      CaseProblemVariantFreeText: N/A

      ClinVarID: N/A

      CAID: CA357012, https://reg.clinicalgenome.org/redmine/projects/registry/genboree_registry/allele?hgvsOrDescriptor=NM_000551.3%3Ac.227_229delTCT

      gnomAD: N/A

      VariantEvidence: N/A

      MutationType: inframe_deletion

      CivicName: F76del (c.227_229del)

      MultipleGeneVariants: N/Av

    Tags

    Annotators

    URL

    1. 91Yes3111––344 del A2Frameshift at aa 115hFrameshiftNovel

      GroupID: None

      KindredID:9

      DiseaseAssertion: VHL

      GroupSize: 3

      GroupNumberMales: N/A

      GroupNumberFemales: N/A

      GroupEthnicity: American Admixed/Latino

      GroupAgeRange: N/A

      GroupInfo: Three members of a South American family expressed this c.344delA mutation.

      GroupPresentingHPOs: HP:0010797, HP:0009711, HP:0005584 (hemangioblastoma, retinal capillary hemangioma, renal cell carcinoma)

      GroupHPOFreeText: N/A

      GroupNotHPOs: HP:0002894, HP:0002666 (neoplasm of the pancreas, pheochromocytoma )

      GroupNotHPOFreeText: N/A

      GroupPreviousTesting: N/A

      PreviouslyPublished: N/A

      SupplementalData: N/A

      Variant: p.H115Pfs*44 (c.344delA)

      LegacyVariant: N/A

      CaseProblemVariantFreeText: N/A

      ClinVarID:N/A

      CAID: CA70049370 https://reg.clinicalgenome.org/redmine/projects/registry/genboree_registry/allele?hgvsOrDescriptor=NM_000551.3%3Ac.344delA

      gnomAD: N/A

      VariantEvidence: N/A

      MutationType: minus_1_frameshift_variant

      CivicName: H115Pfs*44(c.344delA) and P61=(c.183C>G)

      MultipleGeneVariants: Germline, VHL,c.c.183C>G (p.Pro61Pro)

  4. Aug 2026
  5. Mar 2026
  6. Jan 2026
    1. Typewriter Profile: Comparing the Olivetti Lettera 22, Lettera 32, and Studio 44<br /> by [[Damon Di Marco]] of CreateX3.com on YouTube<br /> accessed on 2026-01-19T11:32:11

      Marcello Nizzoli designed the Olivetti Lettera 22, an ultra-portable, and the standard Lexicon 80. He used the automotive idea of press-forming steel to the Olivetti line.

      In 1959, the Illinois Institute of Technology chose the Olivetti Lettera 22 as the best designed product of the last 100 years. It also won the Compasso D'Oro Award in 1954.

      1963 Lettera 32 introduced<br /> Square keys

      1965 Olivetti Studio 44 introduced<br /> Between the standard and the portable<br /> Comes with a case, but is heavier than many portables

      Prefer original spools with spool nuts.

  7. Nov 2025
  8. May 2025
  9. Apr 2025
  10. Mar 2025
    1. The machine was produced in four different versions: Series I with a beige body and black round keys borrowed from its more portable sister machine, the Olivetti Lettera 22 Series II with beige body and black ergonomic keys intended to conform better to the user’s fingers Series III with light blue body, grey-blue keys and knobs Studio 44 L with body from former competitor Underwood (Olivetti bought a controlling interest in Underwood in 1959, and completed a full merger in 1963)

      variations of the Olivetti Studio 44

  11. Dec 2024
  12. Oct 2024
  13. Jul 2024
    1. Olivetti Lettera 31 (Another name for the Dora -- or is it the opposite?) olivetti Dora (the actual base model if I'm not mistaken, with a bunch of rebrands worldwide) ETON (naturally this belongs on this list, I've even seen 2 others for sale online since) Underwood 315 (rebrand) Montgomery Ward Escort 33 (rebrand) Olivetti Underwood 310 (pretty sure this is a rebrand too, or at least very closely related) Olivetti Index (this is the closest thing I've found to my ETON branded one. It s PRACTICALLY the same in every regard - seen two online for sale) Montgomery ward escort 44 (also a rebrand of the DORA?!) Mercedes Super T (rebrand as well, seen one for sale) Montomery Ward Escort 77 (pretty close to being the same model again again... But not quite?) Neckermann BRILLANT Special T (DEFINITELY a rebrand. The manual is a dead give-away among other things) JUPITER (A typewriter 100% identical to the IDEX or ETON, but rebranded again again) Underwood 314 (no idea on this one. I gave up at this point)

      https://typewriterdatabase.com/19xx-olivetti-eton.23086.typewriter

  14. Mar 2024
    1. "Il résulte donc de ce qui précède, qu’en l’absence d’obstacle juridique, l’organe délibératif de l’EPLE est parfaitement libre d’adopter le principe d’une répartition de l’année scolaire en deux semestres, au lieu de trois trimestres. Une fois cette résolution arrêtée, il conviendra également de modifier en conséquence le règlement intérieur de l’établissement."

  15. Oct 2023
    1. after Jacob left Laban’s house with his wives Leah and Rachel. Laban pursued him to get back the idols that Rachel had stolen. After Laban was convinced that Jacob had not stolen his idols, Jacob and Laban make a covenant. “Jacob took a stone (ʼben) and set it up as a pillar (massebah) which would be a witness of the agreement they had made on that occasion (Genesis 31:44–45).
    2. There are several occasions where the massebah is not associated with pagan worship. When the massebah is associated with the worship of Yahweh, the massebah is accepted as a valid expression of commitment to Yahweh.

      Massebah for pagan worship: - Exodus 23:24 (https://hypothes.is/a/r3m5QmyDEe6SC8eLYcJE1Q) - Hosea 10:1 (https://hypothes.is/a/4PK2GGyDEe6wZg_r2YpVCA ) - 2 Kings 18:4 - 2 Kings 23:14

      Massebah for worship of Yahweh: - Genesis 28:18 Jacob's pillow (https://hypothes.is/a/NF5p8Gx6Ee65Rg_J4tfaMQ)<br /> - Genesis 31:44-45 Jacob and Laban's covenant - Exodus 24:4 - Joshua 24:25-27

  16. Apr 2023
  17. Feb 2023
    1. such processing can still be associated with increased risks because it takes place outside the EU, for example due to conflicting national laws or disproportionate government access in a third country.

      So even if you don't need to consider Chapter V, consider Chapter 5.

      I wish the EDPB would just come out and say they want to splinter the internet already. It would be faster.

    2. Example 12: Controller in the EU uses a processor in the EU subject to third country legislationThe Danish Company X, acting as controller, engages Company Y established in the EU as a processoron its behalf. Company Y is a subsidiary of the third country parent Company Z. Company Y isprocessing the data of Company X exclusively in the EU and there is no one outside the EU, includingthe parent Company Z, who has access to the data. Additionally, it follows from the contract betweenCompany X and Company Y that Company Y shall only process the personal data on documentedinstructions from Company X, unless required to do so by EU or Member State law to which CompanyY is subject. Company Y is however subject to third country legislation with extraterritorial effect,which in this case means that Company Y may receive access requests from third country authorities.Since Company Y is not in a third country (but an EU company subject to Article 3(1) GDPR), thedisclosure of data from the controller Company X to the processor Company Y does not amount to atransfer and Chapter V of the GDPR does not apply. As mentioned, there is however a possibility thatCompany Y receives access requests from third country authorities and should Company Y comply withsuch request, such disclosure of data would be considered a transfer under Chapter V. Where CompanyY complies with a request in violation of the controller’s instructions and thus Article 28 GDPR,Company Y shall be considered an independent controller of that processing under Article 28(10)GDPR. In this situation, the controller Company X should, before engaging the processor, assess thesecircumstances in order to ensure that, as required by Article 28 GDPR, it only uses processors providingsufficient guarantees to implement appropriate technical and organisational measures so that theprocessing is in line with the GDPR, including Chapter V, as well as to ensure that there is a contract orlegal act governing the processing by the processor.

      Not a transfer until the USG triggers a request, in which case Company Y becomes an independent controller ... though who is the data being transferred to? The USG on compelled order?

    3. Some examples of how personal data could be “made available” are by creating an account, grantingaccess rights to an existing account, “confirming”/”accepting” an effective request for remote access,embedding a hard drive or submitting a password to a file. It should be kept in mind that remote accessfrom a third country (even if it takes place only by means of displaying personal data on a screen, forexample in support situations, troubleshooting or for administration purposes) and/or storage in acloud situated outside the EEA offered by a service provider, is also considered to be a transfer,provided that the three criteria outlined in paragraph 9 above are met.

      Everything is a transfer.

    4. Example 9: A subsidiary (controller) in the EU shares data with its parent company (processor) in athird countryThe Irish Company X, which is a subsidiary of the parent Company Y in a third country, disclosespersonal data of its employees to Company Y to be stored in a centralised HR database by the parentcompany in the third country. In this case the Irish Company X processes (and discloses) the data in itscapacity of employer and hence as a controller, while the parent company is a processor. Company Xis subject to the GDPR pursuant to Article 3(1) for this processing and Company Y is situated in a thirdcountry. The disclosure therefore qualifies as a transfer to a third country within the meaning ofChapter V of the GDPR.

      The EDPB says "Hahaha, get wrecked"

    5. n addition, this second criterion cannot be considered as fulfilled when there is no controller orprocessor sending or making the data available (i.e. no “exporter”) to another controller or processor,such as when data are disclosed directly by the data subject15 to the recipient.

      No transfer when an action is done directly by a data subject to/from a recipient.

    6. Example 8: Employee of a controller in the EU travels to a third country on a business tripGeorge, employee of A, a company based in Poland, travels to a third country for a meeting bringinghis laptop. During his stay abroad, George turns on his computer and accesses remotely personal dataon his company’s databases to finish a memo. This bringing of the laptop and remote access ofpersonal data from a third country, does not qualify as a transfer of personal data, since George is notanother controller, but an employee, and thus an integral part of the controller (A).19 Therefore, thetransmission is carried out within the same controller (A). The processing, including the remote accessand the processing activities carried out by George after the access, are performed by the Polishcompany, i.e. a controller established in the Union subject to Article 3(1) of the GDPR. It can, however,be noted that in case George, in his capacity as an employee of A, would send or make data availableto another controller or processor in the third country, the data flow in question would amount to atransfer under Chapter V; from the exporter (A) in the EU to such importer in the third country.

      Ah, the employee example. Which of course goes sideways if you start to look at contractors, things get gross.

      Also, 'make the data available' is broad.

    7. Chapter V does not apply to “internal processing”, i.e. where data is not disclosed bytransmission or otherwise made available to another controller or processor, including where suchprocessing takes place outside the EU

      They actually seem to clarify that intra-group processing activities here aren't covered, provided it's truly "internal" - I suspect that if the processing includes contractors, this goes out the window.

  18. Mar 2022
    1. “This is what the Lord says— Israel’s King and Redeemer, the Lord Almighty: I am the first and I am the last; apart from me there is no God” (Isaiah 44:6).

      Jewish monotheism doesn't emerge until the end of the Babylonian Exile (~586 - 500 BCE) period and the beginning of the Second Temple period (500 BCE - 70 CE) when the religion moves from acknowledging the existence of other gods to saying there is only one god. (Isaiah 44:6).

  19. Mar 2021
    1. Results for individual PALB2 variants were normalized relative to WT-PALB2 and the p.Tyr551ter (p.Y551X) truncating variant on a 1:5 scale with the fold change in GFP-positive cells for WT set at 5.0 and fold change GFP-positive cells for p.Y551X set at 1.0. The p.L24S (c.71T>C), p.L35P (c.104T>C), p.I944N (c.2831T>A), and p.L1070P (c.3209T>C) variants and all protein-truncating frame-shift and deletion variants tested were deficient in HDR activity, with normalized fold change <2.0 (approximately 40% activity) (Fig. 1a).

      AssayResult: 3.7

      AssayResultAssertion: Indeterminate

      StandardErrorMean: 0.13

    1. Most Suspected Brugada Syndrome Variants Had (Partial) Loss of Function

      AssayResult: 114.3

      AssayResultAssertion: Abnormal

      ReplicateCount: 16

      StandardErrorMean: 22.4

      Comment: This variant had normal peak current and increased late current (>1% of peak), therefore it was considered a GOF variant (in vitro features consistent with Long QT Syndrome Type 3). (Personal communication: A. Glazer)

  20. Feb 2021
  21. Sep 2020
  22. Apr 2019